CONSTELLATION TECHNOLOGIES LIMITED — Regulatory Filings 2003

Apr 8, 2003

Company Announcement

Agenix to expand distribution of Animal Health Products in USA and Europe

Wednesdav 9 April 2003

Brisbane-based biotechnology company Agenix Limited [ASX:AGX] today announced that its wholly-owned subsidiary. AGEN Biomedical Limited, will expand its distribution of animal health products in the USA and Europe and that the company is preparing to appoint new distributors in these two key markets.

AGEN has been working for a considerable time to identify and qualify suitable distributors, to enable the company to expand and grow these markets. "We expect to be able to announce new agreements with these partners within the next two months," said Dr Paul MacLeman, Vice President, AGEN Animal Health. "These distributors will have access to the majority of the US and European animal health markets, providing AGEN with a significant opportunity to grow this business."

AGEN will also now commence, or continue the development of new tests to address growing sections of the animal health market. These new products will add to the company's existing range of products and go to market through new distribution partners.

As part of the new plan, AGEN will terminate its current agreement with Synbiotics Corporation. Agenix renegotiated this agreement in October 2001, aiming to allow it more freedom to act in selecting the best available partner in each region. In the short term AGEN expects to continue to sell product through Synbiotics.

"Synbiotics has undergone significant changes of management and focus over recent years and has not been able to address this market to AGEN's satisfaction for some time," said Dr MacLeman. "We are keen to be able to address and service a far greater market than they are able to access."

AGEN will wind down sales of products to Synbiotics over the next two months. The company expects sales revenue to reduce by around \$1 million for the remainder of this financial year.

For more information contact:

Mr Donald Home	Dr Paul MacLeman
Managing Director	Vice President
Agenix Limited	AGEN Animal Health
Ph: 61 7 3370 6314	61 7 3370 6393

Agenix Limited [ASX:AGX] is a listed company based in Brisbane, Australia, It manufactures, distributes and markets human and veterinary diagnostic test kits, over-the-counter pharmaceuticals and infant care products via its wholly-owned subsidiaries AGEN Biomedical and Milton Pharmaceuticals. Agenix focuses on developing a horizontally-integrated product portfolio to service the needs of the acute phase thrombosis market. Agenix's lead candidate is its high-technology ThromboView® blood clot-imaging project, which is currently undergoing human trials. ThromboView® uses radiolabelled antibodies to locate blood clots in the body, it could revolutionise the \$US 3 billion annual clot diagnostic imaging market. Agenix employs 190 staff and sells its products to more than 50 countries. ThromboView® is a registered trademark of AGEN Biomedical

www.adenix.net